One-stop Technology Platform to Accelerate Drug Discovery and Development
Vernalis (A HitGen Company) integrates fragment-based approaches, protein science, structural biology, biophysics, assay technology and molecular modelling with extensive organic synthesis and medicinal chemistry expertise to enable drug discovery on both established and novel targets. This requires a deep understanding of the techniques involved and a cautious interpretation of data; an approach grounded on two decades of developing and applying fragment-based lead discovery to challenging targets.